Latest In Research

The good news is that treatment options for lung cancer patients are rapidly improving. In the last two years, more treatments have been approved by the United States Food and Drug Administration (FDA) for the treatment of lung cancer than had been approved in the prior ten years. New and life saving treatments, along with clinical trials, are happening rapidly and LCFA is committed to keeping you up to date on the latest, most hopeful and helpful, information.

09/19
2017

Clinical Trial News from UCLA

UCLA Clinical Trials news for September, 2017 News on 4 Clinical Trials at UCLA and TRIO-US facilities: 1. Phase 3 Trial for EGFRm Positive NSCLC Now Open UCLA  announces the opening of CheckMate 722, a phase 3 trial for pati…

09/12
2017

We’re more likely to get cancer than to get married.

This is a wake-up call. One in two people will encounter a cancer diagnosis in their lifetime, which is why a recent report says that, alongside marriage, parenthood, retirement and the death of a parent, cancer is now “a common life mile…

09/12
2017

Opdivo Improves Long-Term Survival in Advanced Lung Cancer

Opdivo outperformed the cancer drug Taxotere in clinical trials of advanced and earlier treated lung cancer. All patients received the treatment as a second line, following one failed platinum-based chemotherapy regimen. The study loo…

09/12
2017

Lung Cancer: Is Your Doctor Screening You for the Best Treatment?

Not every eligible lung cancer patient receives the new, lifesaving therapies they should. Here’s what’s going on and how to keep it from happening to you. Learn More…

09/12
2017

Merck’s immunotherapy, chemo mix shows extended lung cancer gains

Keytruda plus chemo still shows clear benefit 18 months on: Keytruda in combination with chemotherapy for previously untreated advanced lung cancer appears to provide durable benefits, according to an update of a closely watched clinical…

09/7
2017

Blood tumor markers may warn when lung cancer patients are progressing

New study suggests that tumor markers could be useful in monitoring therapeutic outcomes in those with already established NSCLC disease. Learn More…

09/1
2017

Pembrolizumab Shows Promise in Small Cell Lung Cancer

Pembrolizumab (Keytruda) induced an overall response rate (ORR) of 33% in patients with extensive-stage small cell lung cancer (SCLC), according to findings from the open-label, phase Ib KEYNOTE-028 trial published in the Journal of Clinica…

09/1
2017

Changing Treatment Paradigm for ALK-Positive Lung Cancer

The results of recent clinical trials signal a shifting treatment paradigm that moves away from chemotherapy and crizotinib toward next-generation ALK inhibitors as first line therapy for patients with advanced ALK-positive NS…

09/1
2017

Blood test can predict early lung cancer prognosis

Cancer cells obtained from a blood test may be able to predict how early-stage lung cancer patients will fare, a team from the University of Michigan has shown. Learn More More on Liquid Biopsy How do you know if you are at risk fo…

08/29
2017

Blocking Post-MI Inflammation Tied to Fewer Lung Cancer Deaths

Blocking Post-MI Inflammation Tied to Fewer Lung Cancer Deaths: Treatment that targeted inflammation in the postmyocardial infarction (post-MI) setting led to a thought-provoking reduction in lung cancer incidence and mortality, according t…

Research is imperative to improve treatment and management of all diseases and that’s particularly true of lung cancer. It’s creation of new knowledge, it’s discovery. It’s how we learn how to improve management of symptoms, to improve survival. ~Dr. David Johnson